

NO.675 P.1/9

Attorney Docket No.: 5808.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Martin Lehmann

Confirmation No: 4209

FAX RECEIVED

Serial No.: 09/488,265

Group Art Unit: 1652

MAY 0 1 2002

Filed: January 20, 2000

Examiner: D. Ramirez

GROUP 1600

For: Improved Phytases

CERTIFICATE OF FACSIMILE TRANSMISSION

OFFICE

Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)

2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner D. Ramirez, fax number (703) 308-4556.

Respectfully submitted,

Date: April 30, 2002

Elias J. Lambiris

Novozymes North America, Inc. 405 Lexington Avenue, Suite 6400

New York, NY 10174-6401

(212) 867-0123

NNNP

PATENT

Attorney Docket No.: 5808.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Martin Lehmann

Confirmation No: 4209

Serial No.: 09/488,265

Group Art Unit: 1652

Filed: January 20, 2000

Examiner: D. Ramirez

For: Improved Phytases

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed October 31, 2001.

It is respectfully requested that the time for response to the Office Action be extended for a period of three months from January 31, 2002 to April 30, 2002. The required fee for the extension is estimated to be \$920.

No additional claims fee is required.

Please charge the required extension and claims fees, estimated to be \$920, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: April 30, 2002

05/02/2002 MBROWN 00000002 501701 09488265

01 FC:117 920.00 CH

Elias J. Lambiris, Reg. No. 33,728 Novozymes North America, Inc. 405 Lexington Avenue, Suite 6400

New York, NY 10174-6401

(212) 867-0123